New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, ...

Under a program designed to accelerate the approval of products that could address key national priorities, the FDA awarded a ...

From 2017 to 2024, newly diagnosed multiple myeloma (MM) patients rapidly received quadruplet therapies over triplets, with ...

The FDA has “proactively” granted Johnson & Johnson a coveted speedy review under the Commissioner’s National Priority ...

The complete response or better rate was 81.1% with the combination versus 31.1% in the control arm, while patients treated ...

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive ...

Strong positive results of a novel combination of two immunotherapy drugs as a treatment for multiple myeloma after other treatments have failed suggest the combination could be a “functional cure,” ...

The FDA has awarded its latest national priority voucher to Johnson & Johnson’s Tecvayli (teclistamab-cqyv) in combination with daratumumab for the treatment of relapsed or refractory multiple myeloma ...

In a 2024 review, Richardson and colleagues noted that the immunomodulatory drugs thalidomide, lenalidomide (Revlimid), and ...

A proposed combination of Johnson & Johnson’s multiple myeloma bispecific Tecvayli has turned up positive trial data that ...

A study reveals the gut microbiome's role in predicting multiple myeloma outcomes, highlighting butyrate-producing bacteria ...

Many abstracts about myeloma being presented at ASH 2025 were also presented at the International Myeloma Society (IMS) ...